Try Ask OE! Our NEW Advanced AI Enabled Search
Dive into the Largest Database of
Musculoskeletal Evidence
Sativex as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial
This report has been verified by one or more authors of the original publication.
Int J Neurosci. 2018 Sep 13:1-10.
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Sativex and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis
J Neurol. 2015 Nov;262(11):2520-7
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Effects on Spasticity and Neuropathic Pain of an Oral Formulation of delta9-Tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis
Clin Ther. 2018 Sep;40(9):1467-1482. doi: 10.1016/j.clinthera.2017.01.016